Report Description Table of Contents How Are Hybrid Scanner Installations and Changing Nuclear Medicine Demand Reshaping the Global SPECT Market? – (Updated On: 17th-Nov-2026) According to Strategic Market Research, the Global Single Photon Emission Computed Tomography (SPECT) Market was valued at USD 2.36 billion in 2025 and is projected to reach USD 3.35 billion by 2032, growing at a CAGR of 5.1% during 2026–2032. Replacement of standalone scanners, continued cardiac and skeletal imaging, and increasing availability of hybrid SPECT/CT systems are supporting equipment-market growth. Why Are Hybrid SPECT/CT Systems Becoming More Important to Nuclear Medicine? Established myocardial perfusion examination volumes provide an important foundation for SPECT utilization. An indicative 17.5 million myocardial perfusion imaging examinations are performed worldwide annually, based on the midpoint of historical international estimates. The figure includes myocardial perfusion imaging performed with SPECT and PET, rather than all SPECT examinations. Nevertheless, it demonstrates the substantial clinical demand associated with nuclear cardiac imaging and the importance of maintaining established diagnostic services. Source: UNSCEAR Global Medical Exposure Report The replacement of conventional SPECT scanners with hybrid equipment is an established source of market demand. Canada's Medical Imaging Inventory recorded 331 SPECT/CT systems and 210 standalone SPECT systems in 2022–2023. More recent developments demonstrate continued investment in the technology. In August 2026, the Saskatchewan Health Authority reported that two GE HealthCare StarGuide SPECT/CT scanners had entered operation at Regina General Hospital and Royal University Hospital, supported by CAD 2.1 million in provincial investment and a CAD 2 million foundation contribution, respectively. Since the first installation in April 2025, the authority reported 2,856 examinations involving 1,634 patients. These figures provide direct evidence of new SPECT/CT installations, associated investment, and clinical utilization, reinforcing the commercial importance of hybrid equipment modernization. Recent manufacturer developments are introducing additional competition in hybrid imaging. On September 8, 2026, GE HealthCare announced European CE marking for its StarGuide GX SPECT/CT system. The product was awaiting U.S. FDA clearance at the time of the announcement. Its introduction expands GE HealthCare's nuclear imaging portfolio and creates an additional option for hospitals considering newer SPECT/CT systems. Clinical evaluation of advanced SPECT/CT is extending across major international hospitals. In October 2026, GE HealthCare announced five clinical collaborations involving Mayo Clinic in the United States, Peking University First Hospital in China, Oncopole in France, and two institutions in Israel. The company reported experience involving more than 1,000 patient imaging studies. These collaborations demonstrate clinical evaluation of the new platform, although they do not establish commercial installations or SPECT equipment sales. Competition is also expanding beyond the largest multinational imaging manufacturers. In January 2026, the U.S. FDA cleared an update to Spectrum Dynamics Medical's VERITON-CT digital SPECT/CT platform. The company subsequently announced a further product enhancement in July 2026, with initial clinical use at Florida Theranostics. These developments establish Spectrum Dynamics as a direct participant in the advanced SPECT equipment market. The market's growth is therefore increasingly associated with hybrid-system adoption, replacement of older cameras, and competition among dedicated SPECT manufacturers. This provides a more direct basis for assessing equipment revenue than broad nuclear medicine activity alone. Which Product and Technology Segments Lead the Global SPECT Market? Hybrid SPECT/CT Systems — Leading Product Segment Hybrid SPECT/CT systems account for the largest product share at 58%, equivalent to USD 1.369 billion in 2025 revenue, and are projected to grow at a CAGR of 6.2% during 2026–2032. Their leading position reflects the increasing adoption of integrated scanners across established nuclear medicine departments. GE HealthCare's StarGuide, Siemens Healthineers' Symbia Pro.specta, and Spectrum Dynamics' VERITON-CT represent commercial products competing in this category. The segment's projected growth above the overall market CAGR indicates that hybrid systems are expected to capture an increasing portion of SPECT equipment revenue, particularly as facilities replace older standalone scanners. Conventional SPECT — Leading Technology Segment Conventional detector systems hold a dominant 72% market share, representing USD 1.699 billion in 2025 revenue, and are projected to expand at a CAGR of 4.3% during 2026–2032. Their leadership reflects the large installed base of conventional gamma cameras serving routine cardiac, skeletal, and general nuclear medicine examinations. Siemens Healthineers' Symbia portfolio and other established conventional imaging platforms demonstrate continued manufacturer participation in this category. Conventional technology is expected to retain substantial revenue from existing nuclear medicine applications, although its growth remains below the overall market as newer detector systems gain adoption. The commercial outlook differs between these two leading categories. Hybrid SPECT/CT leads by scanner configuration and is projected to grow faster than the overall market, while conventional SPECT leads by detector technology because of its established equipment base. These categories overlap: a hybrid system can use conventional detectors. Their respective shares therefore describe different classifications of the same global equipment revenue and must not be added together. Which Clinical Application Generates the Largest SPECT Market Revenue? Cardiology — Leading Application Segment Cardiology accounts for the largest application share at 45%, equivalent to USD 1.062 billion in 2025 revenue, and is projected to grow at a CAGR of 4.8% during 2026–2032. Myocardial perfusion imaging remains an established application for SPECT equipment in the assessment of coronary artery disease and myocardial ischemia. An indicative 7.5 million SPECT myocardial perfusion imaging procedures annually in the United States represents the midpoint of an older published utilization range, rather than an observed current annual count. A 2025 study of U.S. Medicare nuclear cardiology activity reported approximately 1.386 million cardiac SPECT procedures in 2022, compared with 2.303 million in 2013. This Medicare-specific decline demonstrates that historical national estimates should not be treated as current demand. Cardiology's leading revenue position is supported by established myocardial perfusion services and dedicated cardiac imaging equipment. However, the decline in Medicare examinations and competition from cardiac PET indicate that future equipment revenue will depend more on scanner replacement and utilization within existing services than on consistently increasing cardiac SPECT procedure volumes. What Role Do Radioisotopes Play in SPECT Examination Demand? Technetium-99m remains the principal isotope associated with SPECT examinations, particularly in myocardial perfusion, skeletal, renal, and other organ-specific imaging. Its widespread clinical use supports the operation of conventional and hybrid scanners. However, isotope consumption should not be presented as a direct percentage of SPECT equipment revenue because the same imaging system can perform examinations using several radiopharmaceuticals. Iodine-123 contributes through selected neurological and thyroid examinations, including dopamine transporter imaging. Thallium-201 retains an established but narrower role in cardiac perfusion studies. Other isotopes, including indium-111 and certain radionuclides used during treatment assessment, support specialized nuclear medicine applications. These clinical categories are relevant to scanner utilization and equipment capabilities. The supplied estimates allocating 80% of equipment-market revenue to technetium-99m, 8% to iodine-123, 5% to thallium-201, and 7% to other isotopes require a separate attribution model before being used as revenue segments. Why Do Hospitals Lead SPECT Equipment Revenue? Hospitals account for the largest end-user share at 58% of the global SPECT Market, equivalent to USD 1.369 billion in 2025 revenue, and are projected to grow at a CAGR of 4.8% during 2026–2032. Their leading position is supported by established nuclear medicine departments conducting myocardial perfusion studies, skeletal imaging, cancer-related examinations, and specialized neurological investigations. According to Canada's Medical Imaging Inventory, 73% of responding facilities with SPECT/CT equipment were hospitals, demonstrating the concentration of hybrid imaging systems within hospital-based services. This evidence supports hospitals' leading commercial position, with replacement of existing scanners and adoption of hybrid SPECT/CT expected to remain important contributors to hospital equipment revenue through 2032. Where Is SPECT Equipment Investment Most Evident Across Global Markets? North America: Established Imaging Demand and Measurable Replacement Activity North America accounts for the largest regional share at 38%, representing USD 897 million in 2025 revenue, and is projected to grow at a CAGR of 4.6% during 2026–2032. The regional market combines a large established scanner base in the United States with documented replacement of conventional cameras in Canada. United States: The country accounts for an estimated 32.3% of global market revenue, equivalent to USD 762 million in 2025, and is projected to grow at a CAGR of 4.5%. The U.S. market has established cardiac SPECT services and an active commercial market for advanced systems. In July 2026, Spectrum Dynamics reported initial clinical use of its enhanced VERITON-CT platform at Florida Theranostics. This provides direct evidence of a newer SPECT/CT system entering clinical use in the country. Source: Spectrum Dynamics Canada: The Canadian Medical Imaging Inventory recorded 929,010 combined SPECT and SPECT/CT examinations in 2022–2023, equivalent to an average of approximately 2,807 examinations per installed system. The same report found that the combined examination volume had declined from 1.49 million in 2015. These findings identify an important distinction for Canada's market: hybrid scanner installations have expanded even as reported examination activity has fallen. The commercial opportunity is therefore more clearly associated with equipment replacement and changes in scanner type than with uniform growth in testing volume. Europe: Established Cardiac SPECT Activity and New Hybrid Imaging Evaluation Europe accounts for 27% of global SPECT revenue, equivalent to USD 637 million in 2025, and is projected to grow at a CAGR of 4.8%. The region includes established nuclear medicine markets with different levels of hybrid scanner adoption, particularly across Germany, the United Kingdom, and France. Germany: A 2026 study covering myocardial perfusion imaging activity in 2024 recorded 128,707 SPECT examinations across 198 participating German departments. The study also reported that 56% of German facilities used standalone SPECT cameras as their principal cardiac imaging systems, demonstrating the continued relevance of conventional equipment. These findings identify an established cardiac imaging market with a substantial conventional scanner presence. United Kingdom: NHS England's April 2026 statistical release recorded 61,725 SPECT examinations for NHS patients in England during January–December 2025, based partly on provisional data. The figure establishes directly reported examination activity rather than an estimated national scanner market. Continued use of SPECT within NHS imaging services supports an identifiable installed-equipment requirement, although the number of annual examinations does not independently establish new scanner sales. France: In October 2026, GE HealthCare identified Oncopole Claudius Regaud in Toulouse as one of five international institutions participating in clinical evaluation of StarGuide GX. The French collaboration provides evidence of active assessment of a new SPECT/CT platform within oncology-focused nuclear medicine. It establishes an important link between French specialist imaging services and current manufacturer development, although it does not represent a confirmed commercial purchase. Asia-Pacific: Hybrid Installations and Established National Imaging Activity Asia-Pacific accounts for 25% of global market revenue, equivalent to USD 590 million in 2025, and is projected to record the fastest regional CAGR of 7.0%. China provides direct evidence of expanding hybrid equipment installations, while Japan has an established installed scanner base and substantial clinical SPECT activity. China: The country accounts for an estimated 10% of global market revenue, equivalent to USD 236 million in 2025, and is projected to grow at a CAGR of 8.5%. A 2025 review of national nuclear medicine surveys reported 686 SPECT/CT scanners in 2023, compared with 169 in 2009. During the same period, standalone SPECT installations declined from 386 to 277. The equipment data demonstrate a clear transition toward hybrid imaging. They also indicate that China's future SPECT equipment revenue is more closely linked to integrated scanner adoption than expansion of standalone installations. Source: Chinese Nuclear Medicine Survey Japan: A nationwide nuclear medicine survey published in 2024 identified 1,299 installed gamma cameras in its 2022 assessment, with hybrid SPECT/CT systems accounting for 35.5% of the reported camera base. SPECT studies represented 66.8% of examinations involving single-photon tracers. These findings establish Japan as a substantial installed-base market, with ongoing demand associated with existing cardiac, skeletal, and neurological nuclear medicine services. The figures represent the latest nationwide survey identified here rather than a verified 2025 installed base. Latin America: New SPECT/CT Installations Demonstrate Equipment Investment Latin America accounts for 5% of the global market, equivalent to USD 118 million in 2025 revenue, and is projected to grow at a CAGR of 5.0%. Brazil provides recent, direct evidence of investment in nuclear medicine imaging equipment. In October 2026, Brazil's Ministry of Health reported the installation of a new SPECT/CT system at the Hospital de Clínicas of the University of Campinas. The ministry reported an investment exceeding BRL 8.6 million and identified the system's role in cancer-related imaging. This provides a concrete example of SPECT/CT capital investment in a public healthcare institution, rather than relying on general statements about nuclear medicine expansion. Middle East & Africa: Documented Hybrid Installations Support Market Participation The Middle East & Africa accounts for 5% of market revenue, equivalent to USD 118 million in 2025, and is projected to grow at a CAGR of 5.5%. South Africa provides directly identifiable examples of SPECT/CT installations in both public and private healthcare settings. The University of the Free State reported the installation of two Siemens Pro.specta SPECT/CT systems at Universitas Hospital during 2025. Separately, Life Healthcare announced in June 2026 that its new nuclear medicine unit at Life Hilton Private Hospital would offer both PET/CT and SPECT/CT services. These developments establish recent commercial activity involving hybrid imaging in South Africa. The regional market remains concentrated in facilities with dedicated nuclear medicine services, and the available installation evidence does not independently determine total regional equipment sales. Which Manufacturers Are Competing for SPECT Equipment Revenue? GE HealthCare: New StarGuide Systems Expand Its Hybrid Imaging Portfolio GE HealthCare maintains a direct SPECT market presence through its StarGuide portfolio and established nuclear medicine systems. The company's September 2026 announcement of StarGuide GX's European CE marking and its October 2026 international clinical evaluation program provide recent evidence of continued product development. These activities strengthen its presence in newer hybrid SPECT/CT systems and specialized nuclear medicine applications. GE HealthCare reported USD 9.245 billion in Imaging segment revenue during 2025, but this figure covers multiple imaging modalities. It cannot be used as a proxy for SPECT-specific revenue. Source: GE HealthCare 2025 Annual Filing Siemens Healthineers: Standalone and Hybrid SPECT Portfolios Siemens Healthineers competes through its Symbia family, including Symbia Pro.specta and Symbia Intevo SPECT/CT systems, alongside Symbia Evo standalone scanners. Its current portfolio covers both major product categories in the market. The company's established scanner offerings are particularly relevant to countries maintaining significant conventional nuclear medicine installations while gradually introducing hybrid equipment. The presence of Siemens systems in South Africa's 2025 hospital installations provides an identifiable example of recent clinical deployment. Source: Siemens Healthineers SPECT Portfolio Spectrum Dynamics Medical: Direct Competition in Digital SPECT Spectrum Dynamics Medical participates through the VERITON-CT and D-SPECT product families. The company's January 2026 U.S. FDA clearance and July 2026 VERITON-CT enhancement establish continued commercialization activity in digital SPECT/CT. Its portfolio is particularly relevant to specialized cardiac imaging and advanced nuclear medicine services. Source: Spectrum Dynamics Medical Mediso: Specialist Supplier of Standalone and Hybrid Systems Mediso offers AnyScan standalone SPECT, SPECT/CT, and integrated nuclear imaging systems. Its portfolio includes the AnyScan TRIO and DUO families, allowing participation across conventional and hybrid nuclear medicine equipment categories. The company introduced its TRIO-TheraMAX SPECT/CT platform in 2024, establishing a recent addition to its commercial product offering. Source: Mediso Product Portfolio What Could Influence the SPECT Market Forecast Through 2032? The principal growth opportunity is associated with hybrid equipment. Installed-base evidence from Canada and China demonstrates that hybrid scanners are gaining share while standalone equipment is declining, supporting an investment outlook centered on modernization. However, examination volumes do not necessarily increase alongside equipment installations. Canada's reported decline in combined SPECT examinations and the reduction in U.S. Medicare cardiac SPECT activity show that scanner utilization can change even when equipment technology advances. Competition from cardiac PET and other imaging methods also creates uncertainty for established cardiac applications. Newer SPECT/CT products and continued evaluation of CZT systems provide opportunities for manufacturers serving specialized nuclear medicine. Their commercial contribution will depend on actual installations and the revenue associated with new equipment, rather than clinical collaboration announcements alone. Research Methodology: How Was the SPECT Equipment Market Assessed? The Global SPECT Market assessment covers standalone SPECT scanners, hybrid SPECT/CT equipment, and directly associated imaging-system revenue. It excludes the independent sale of radiopharmaceuticals, PET-only scanners, and charges for performing nuclear medicine examinations. Market estimates are evaluated using country-level installed scanner counts, replacement of standalone equipment, documented SPECT examination volumes, current manufacturer product portfolios, and relevant regulatory approvals. Installed equipment and examination volumes are used to assess commercial demand but are not treated as equipment revenue themselves. Product, detector technology, clinical application, end user, and regional classifications represent different views of the same market. Radioisotope usage is treated as supporting clinical evidence rather than an independently additive equipment-revenue category. The base year is 2025, and the forecast period is 2026–2032. The global valuation and segment allocations represent Strategic Market Research estimates requiring reconciliation with manufacturer-specific SPECT sales and scanner installation data. Single Photon Emission Computed Tomography (SPECT) Market Report Coverage Table Report Attribute Details Forecast Period 2026 – 2032 Market Size Value in 2025 USD 2.36 Billion Revenue Forecast in 2032 USD 3.35 Billion Overall Growth Rate CAGR of 5.1% (2026 – 2032) Base Year for Estimation 2025 Historical Data 2019 – 2024 Unit USD Million/Billion, CAGR (2026 – 2032) Segmentation By Product Type, By Detector Technology, By Clinical Application, By End User, By Geography By Product Type Standalone SPECT Systems, Hybrid SPECT/CT Systems By Detector Technology Conventional Detector Systems, Cadmium Zinc Telluride (CZT) Detector Systems By Clinical Application Cardiology, Skeletal Imaging, Oncology, Neurology, Other Clinical Applications By End User Hospitals, Other Nuclear Medicine Facilities By Region North America, Europe, Asia-Pacific, Latin America, Middle East & Africa Country Scope U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa Market Drivers Replacement of standalone scanners, adoption of hybrid SPECT/CT systems, sustained cardiac and skeletal imaging demand, investment in nuclear medicine equipment Customization Option Available upon request Frequently Asked Question About This Report Q1. Why are healthcare facilities shifting toward hybrid systems in the SPECT market? A1. Hospitals are replacing older standalone scanners with hybrid SPECT/CT systems to support cardiac and other nuclear medicine examinations. Canada's 2022–2023 medical imaging inventory recorded 331 SPECT/CT systems compared with 210 standalone scanners. Hybrid systems account for 58% of global market revenue in 2025 and are projected to grow at a CAGR of 6.2% through 2032. Q2. What are the latest advancements introduced by industry players? A2. GE HealthCare received European CE marking for its StarGuide GX SPECT/CT system in September 2026. Spectrum Dynamics Medical also received FDA clearance for an update to its VERITON-CT platform in January 2026. These developments are expanding the range of advanced hybrid imaging systems available to nuclear medicine providers. Q3. How is demand changing across different regions of the SPECT market? A3. North America leads with a 38% revenue share in 2025, while Asia-Pacific is projected to grow fastest at a CAGR of 7.0% through 2032. China's SPECT/CT scanner count increased from 169 in 2009 to 686 in 2023. This expansion demonstrates the region's growing investment in hybrid nuclear imaging equipment. Q4. Which industries are using SPECT technology the most? A4. Hospitals are the largest end users, accounting for 58% of market revenue in 2025. They use SPECT systems primarily for cardiac perfusion imaging, skeletal examinations, and selected neurological and cancer-related investigations. Canada's imaging inventory found that 73% of responding facilities with SPECT/CT equipment were hospitals. Q5. How is competition evolving among manufacturers in the SPECT industry? A5. GE HealthCare, Siemens Healthineers, Spectrum Dynamics Medical, and Mediso compete through standalone and hybrid imaging systems. GE HealthCare is expanding its StarGuide portfolio, while Spectrum Dynamics is developing its digital VERITON-CT platform. Competition increasingly focuses on replacing conventional scanners and securing hospital equipment investments. Q6. What are the biggest challenges affecting expansion of the SPECT market? A6. Declining examination volumes in some established markets and competition from cardiac PET may affect equipment demand. U.S. Medicare cardiac SPECT procedures declined from approximately 2.303 million in 2013 to 1.386 million in 2022. Manufacturers therefore depend increasingly on scanner replacement and hybrid-system adoption rather than higher examination volumes alone. Q7. How will the SPECT market evolve over the next few years? A7. Hybrid SPECT/CT installations and replacement of conventional cameras are expected to remain important sources of growth. The global market is projected to increase from USD 2.36 billion in 2025 to USD 3.35 billion by 2032 at a CAGR of 5.1%. Asia-Pacific is expected to provide faster growth, while established markets continue investing in equipment modernization. Sources: Saskatchewan Health Authority – Reported Two StarGuide SPECT/CT Installations in August 2026, Supported by CAD 2.1 Million in Provincial Funding and a CAD 2 Million Foundation Contribution; the First Scanner Had Completed 2,856 Examinations for 1,634 Patients Saskatchewan Health Authority – New Scanners Provide Enhanced Diagnostic Care for Patients GE HealthCare – Announced on September 8, 2026, That StarGuide GX Had Received European CE Marking and Was Awaiting U.S. FDA 510(k) Clearance GE HealthCare – StarGuide GX SPECT/CT: European Authorization and U.S. Regulatory Submission GE HealthCare – Announced Five International StarGuide GX Clinical Collaborations on October 20, 2026, Reporting Experience From More Than 1,000 Patient Imaging Studies GE HealthCare – Global Clinical Collaborations for Next-Generation SPECT/CT Imaging U.S. FDA – Cleared Spectrum Dynamics Medical’s VERITON CT 300 and 400 Series Digital SPECT/CT Systems on January 13, 2026, Under 510(k) Number K254001 FDA – VERITON CT Digital SPECT/CT Systems: Regulatory Clearance Spectrum Dynamics Medical – Announced an All-Energy Enhancement to VERITON-CT 400 on July 20, 2026, With Initial Clinical Experience Completed at Florida Theranostics Spectrum Dynamics – VERITON-CT 400 Enhancement and Initial Clinical Deployment NHS England – Reported 61,725 SPECT Examinations for NHS Patients in England During January–December 2025 in Its April 2026 Statistical Release, With Part of the Data Remaining Provisional NHS England – Diagnostic Imaging Dataset: April 2026 Statistical Release Brazilian Ministry of Health – Reported Investment Exceeding BRL 8.6 Million in a SPECT/CT System at Unicamp’s Hospital de Clínicas in October 2026 Brazilian Ministry of Health – SPECT/CT Installation and Cancer Imaging Investment at Unicamp Life Healthcare – Announced a New Nuclear Medicine Unit Offering SPECT/CT and PET/CT Services at Life Hilton Private Hospital in South Africa on June 30, 2026 Life Healthcare – Expansion of Nuclear Medicine Imaging Services in KwaZulu-Natal Mediso – Identifies the 2024 Launch of Its TRIO-TheraMAX SPECT/CT Platform and Lists AnyScan DUO and TRIO Systems Within Its Clinical Imaging Portfolio Mediso – SPECT/CT Product Portfolio and Company Development Timeline Table of Contents - Global Single Photon Emission Computed Tomography (SPECT) Market Report (2026–2032) Executive Summary Market Overview Market Attractiveness by Product Type, Detector Technology, Clinical Application, End User, and Region Strategic Insights from Key Executives (CXO Perspective) Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Summary of Market Segmentation by Product Type, Detector Technology, Clinical Application, End User, and Region Market Share Analysis Leading Players by Revenue and Market Share Market Share Analysis by Product Type, Detector Technology, Clinical Application, and End User Investment Opportunities in the SPECT Market Key Developments and Innovations in SPECT and Hybrid SPECT/CT Systems Mergers, Acquisitions, and Strategic Partnerships High-Growth Segments for Investment Opportunities in Hybrid SPECT/CT Installations, Standalone Scanner Replacement, Digital SPECT, CZT Detector Systems, and Advanced Nuclear Medicine Imaging Market Introduction Definition and Scope of the Study Market Structure and Key Findings Overview of Top Investment Pockets Strategic Importance of SPECT Equipment in Cardiology, Skeletal Imaging, Oncology, Neurology, and Nuclear Medicine Services Role of Hybrid SPECT/CT Systems in Equipment Modernization and Clinical Imaging Research Methodology Research Process Overview Primary and Secondary Research Approaches Market Size Estimation and Forecasting Techniques Data Triangulation and Segment-Level Forecasting Approach Installed Scanner Base, Replacement Demand, and Equipment Revenue Assessment Market Dynamics Key Market Drivers Challenges and Restraints Impacting Growth Emerging Opportunities for Stakeholders Impact of Regulatory Approvals and Healthcare Infrastructure Investment Role of Hybrid SPECT/CT Adoption and Standalone Scanner Replacement in Market Expansion Impact of Cardiac PET Competition and Changes in SPECT Examination Volumes Influence of Radioisotope Availability and Nuclear Medicine Utilization on Equipment Demand Global SPECT Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type: Standalone SPECT Systems Hybrid SPECT/CT Systems Market Analysis by Detector Technology: Conventional Detector Systems Cadmium Zinc Telluride (CZT) Detector Systems Market Analysis by Clinical Application: Cardiology Skeletal Imaging Oncology Neurology Other Clinical Applications Market Analysis by End User: Hospitals Other Nuclear Medicine Facilities Market Analysis by Region: North America Europe Asia-Pacific Latin America Middle East & Africa Market Analysis by Radioisotope Utilization: Technetium-99m, Iodine-123, Thallium-201, and Other Isotopes Leading and Emerging Product and Technology Segments Regional Market Analysis North America SPECT Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type, Detector Technology, Clinical Application, and End User Hybrid SPECT/CT Installations and Standalone Scanner Replacement Trends Cardiac SPECT Utilization and Nuclear Medicine Equipment Investment Country-Level Breakdown: United States Canada Mexico Europe SPECT Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type, Detector Technology, Clinical Application, and End User Cardiac SPECT Activity and Hybrid Imaging Evaluation Conventional Gamma Camera Utilization and Advanced SPECT/CT Adoption Country-Level Breakdown: Germany United Kingdom France Italy Spain Rest of Europe Asia-Pacific SPECT Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type, Detector Technology, Clinical Application, and End User Hybrid SPECT/CT Installation Growth and Standalone Equipment Transition National Gamma Camera Base and Nuclear Medicine Examination Activity Country-Level Breakdown: China India Japan South Korea Australia Rest of Asia-Pacific Latin America SPECT Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type, Detector Technology, Clinical Application, and End User Public Healthcare Investment in Hybrid SPECT/CT Equipment Nuclear Medicine Infrastructure and Cancer Imaging Applications Country-Level Breakdown: Brazil Mexico Rest of Latin America Middle East & Africa SPECT Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type, Detector Technology, Clinical Application, and End User Hospital-Based Hybrid SPECT/CT Installations Public and Private Nuclear Medicine Equipment Investment Country-Level Breakdown: Saudi Arabia United Arab Emirates South Africa Rest of Middle East & Africa Competitive Intelligence and Benchmarking Leading Key Players: GE HealthCare Siemens Healthineers Spectrum Dynamics Medical Mediso Canon Medical Systems Corporation United Imaging Healthcare Digirad Corporation Neusoft Medical Systems Competitive Landscape and Strategic Insights Benchmarking Based on Product Portfolio, Detector Technology, Hybrid Imaging Capabilities, Regulatory Approvals, and Regional Presence Standalone SPECT and Hybrid SPECT/CT Product Portfolio Comparison Conventional Detector and CZT-Based System Positioning Digital SPECT and Advanced Cardiac Imaging Technology Strategies Product Development, Clinical Collaborations, and Equipment Installation Analysis Appendix Abbreviations and Terminologies Used in the Report References and Sources Market Definitions and Equipment Scope Segmentation Definitions and Classification Country-Level Coverage and Regional Classification Research Assumptions and Limitations List of Tables Market Size by Product Type, Detector Technology, Clinical Application, End User, and Region (2026–2032) Historical Market Size and Volume (2019–2024), Base Year Market Size Analysis (2025), and Market Forecasts (2026–2032) Regional Market Breakdown by Product Type, Detector Technology, Clinical Application, and End User Country-Level Market Analysis Across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa Standalone SPECT and Hybrid SPECT/CT Equipment Comparison Conventional Detector and CZT Detector Technology Comparison Competitive Benchmarking of Leading SPECT Equipment Manufacturers Radioisotope Utilization Across Major SPECT Clinical Applications Scanner Installation, Replacement, and Clinical Utilization Trends List of Figures Market Drivers, Challenges, Opportunities, and Restraints Regional Market Snapshot Competitive Landscape by Market Share Growth Strategies Adopted by Key Players Market Share by Product Type, Detector Technology, Clinical Application, and End User (2025 vs. 2032) Global SPECT Equipment Ecosystem and Value Chain Analysis Hybrid SPECT/CT Adoption and Standalone Scanner Replacement Trends Regional Distribution of SPECT and SPECT/CT Installations Global Conventional and CZT Detector Technology Landscape